NGNE supply chain intelligence for Neurogene Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Neurogene Inc. (NGNE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CAPITAL-RESOURCES | CAPITAL-RESOURCES | 62% | ount to support business operations, and (iii) a $0.1 million increase in professional and consultant fees, primarily due to higher patent and IT services costs. These increases were partially offset… |
| COMPANY-PROJECT-NORTH-MERGER-SUB-INC | COMPANY-PROJECT-NORTH-MERGER-SUB-INC | 62% | rowth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Our estimates and forecasts relating to size and expected growth … |
| DELAWARE-GENERAL-CORPORATION | DELAWARE-GENERAL-CORPORATION | 62% | rowth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Our estimates and forecasts relating to size and expected growth … |
| EDINBURGH-VIROVEK-INC | EDINBURGH-VIROVEK-INC | 62% | example, the BIOSECURE Act, enacted in December 2025, restricts the ability of federal agencies and their contractors to work with designated “biotechnology companies of concern.” The implementation … |
| LEERINK-PARTNERS-LLC | LEERINK-PARTNERS-LLC | 62% | e Company entered into a Non-Exclusive License Agreement with the Board of Trustees of Leland Stanford Junior University (the “Stanford License Agreement”) to license, on a non-exclusive basis, certa… |
| NEOLEUKIN-THERAPEUTICS-INC | NEOLEUKIN-THERAPEUTICS-INC | 62% | rowth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Our estimates and forecasts relating to size and expected growth … |
| SIGMA-ALDRICH-CO-LLC | SIGMA-ALDRICH-CO-LLC | 62% | example, the BIOSECURE Act, enacted in December 2025, restricts the ability of federal agencies and their contractors to work with designated “biotechnology companies of concern.” The implementation … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| NGNE-DEBT | Debt stack $9.1M | 90% | Market cache reports total debt of $9.1M. |
| NGNE-DEBT-11256 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2023-12-31. |
| NGNE-DEBT-11255 | Warrants outstanding: 1825635 | 90% | xbrl warrant detail from xbrl 2023-12-18. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| NGNE-OWNER-SAMSARA-BIOCAPITAL-LLC | SAMSARA BIOCAPITAL, LLC | 90% | 13F overlay lists SAMSARA BIOCAPITAL, LLC as top holder; 98 tracked holders. |